BRIEF: Abbisko moves into the black in 2024
Biopharmaceutical company Abbisko Cayman Ltd. (2256.HK) said on Monday that its revenue increased significantly last year, up from 19 million yuan ($2.59 million) in 2023 to 485 million yuan in 2024. As a result, the company earned a profit of 10 million yuan last year, reversing a loss of 432 million yuan the previous year.
The company said the big revenue increase and resulting profit were mostly due to its signing of an out-licensing agreement for its drug pimicotinib (ABSK021), including an upfront payment of $70 million, with Merck (MRK.US).
Shares of Abbisko opened up nearly 1% at HK$4.55 on Monday and continued to rise through the day, up 3.1% in the afternoon session. The company’s shares have more than doubled over the past year.
By Lau Chi Hang
To subscribe to Bamboo Works weekly free newsletter, click here
Related Articles
BRIEF: Alibaba to develop AI-powered iPhone with Apple for China
BRIEF: Production begins at Ganfeng Lithium’s Mariana project
BRIEF: SMIC’s fourth-quarter revenue jumps, but profit falls
RELATED ARTICLES
-
Forget about growth. Qifu shows it’s all about giving back to shareholders
QFIN.US -
Dingdong rings back to revenue growth, posts quarterly net profit
DDL.US
- Baiwang eyes Hong Kong IPO to support its money-hungry loan facilitation business
-
JD rights its shopping cart with first-quarter turnaround
9618.HK JD.US
-
Fosun moves on from debt crisis with renewed focus on tourism, healthcare
0656.HK
-
Nissin Foods serves up profit gains even as revenue declines
1475.HK
-
Shandong Fengxiang falls afoul of sagging poultry prices
9977.HK
